The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Heparin: Past, Present, and Future
Open accessAbstract
Heparin, the most widely used anticoagulant drug in the world today, remains an animal-derived product with the attendant risks of adulteration and contamination. A contamination crisis in 2007–2008 increased the impetus to provide non-animal-derived sources of heparin, produced under cGMP conditions. In addition, recent studies suggest that heparin may have significant antineoplastic activity, separate and distinct from its anticoagulant activity, while other studies indicate a role for heparin in treating inflammation, infertility, and infectious disease. A variety of strategies have been proposed to produce a bioengineered heparin. In this review, we discuss several of these strategies including microbial production, mammalian cell production, and chemoenzymatic modification. We also propose strategies for creating “designer” heparins and heparan-sulfates with various biochemical and physiological properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Garcia, D. A., Baglin, T. P., Weitz, J. I., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2291 · Cited by 1,091
Heparin and Low-Molecular-Weight Heparin
Hirsh, J., Warkentin, T. E., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (1998) · Chest · doi:10.1378/chest.114.5_supplement.489s · Cited by 1,031
Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis
Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai-Michaeli, R., Bitan, M., Pappo, O., Peretz, T., Michal, I., et al. (1999) · Nature Medicine · doi:10.1038/10518 · Cited by 803
The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line
Xu, X., Nagarajan, H., Lewis, N. E., Pan, S., Cai, Z., Liu, X., Chen, W., Xie, M., Wang, W., Hammond, S., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1932 · Cited by 785
Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M., & Varki, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061615598 · Cited by 714
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events
Guerrini, M., Beccati, D., Shriver, Z., Naggi, A., Viswanathan, K., Bisio, A., Capila, I., Lansing, J. C., Guglieri, S., Fraser, B., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1407 · Cited by 628
Self-citationMolecular properties and involvement of heparanase in cancer metastasis and angiogenesis
Vlodavsky, I., & Friedmann, Y. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13662 · Cited by 618
Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation
Nelson, R., Cecconi, O., Roberts, W., Aruffo, A., Linhardt, R., & Bevilacqua, M. (1993) · Blood · doi:10.1182/blood.v82.11.3253.3253 · Cited by 516
Self-citationStructure and Biological Activity of Heparin
Casu, B. (1985) · Advances in Carbohydrate Chemistry and Biochemistry · doi:10.1016/s0065-2318(08)60067-0 · Cited by 428
The anti-inflammatory effects of heparin and related compounds
Young, E. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2006.10.026 · Cited by 390
Pharmacokinetic and Pharmacodynamic Properties of Oral Anticoagulants, Especially Phenprocoumon
Haustein, K.-O. (1999) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2007-996417 · Cited by 387
Structure of the antithrombin-binding site in heparin.
Lindahl, U., Bäckström, G., Höök, M., Thunberg, L., Fransson, L. A., & Linker, A. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.7.3198 · Cited by 368
Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4
Lane, D. A., Denton, J., Flynn, A. M., Thunberg, L., & Lindahl, U. (1984) · Biochemical Journal · doi:10.1042/bj2180725 · Cited by 342
Wang, L., Brown, J. R., Varki, A., & Esko, J. D. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14996 · Cited by 314
Wang, L., Brown, J. R., Varki, A., & Esko, J. D. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214996 · Cited by 288
Masquerading microbial pathogens: capsular polysaccharides mimic host-tissue molecules
Cress, B. F., Englaender, J. A., He, W., Kasper, D., Linhardt, R. J., & Koffas, M. A. G. (2014) · FEMS Microbiology Reviews · doi:10.1111/1574-6976.12056 · Cited by 282 · cited 1×
“Further work showcased a system whereby a heparosan backbone [31] was converted into a product more similar to pharmaceutical heparin through N-deacetylation and N-sulfation steps, followed by modification by recombinant C5 epimerase and OSTs [26].”
BackgroundSelf-citationDifferent Heparan Sulfate Proteoglycans Serve asCellular Receptors for HumanPapillomaviruses
Shafti-Keramat, S., Handisurya, A., Kriehuber, E., Meneguzzi, G., Slupetzky, K., & Kirnbauer, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.24.13125-13135.2003 · Cited by 279
Heparin and Heparan Sulfate Biosynthesis
Sugahara, K., & Kitagawa, H. (2002) · IUBMB Life · doi:10.1080/15216540214928 · Cited by 259
Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review
Mousavi, S., Moradi, M., Khorshidahmad, T., & Motamedi, M. (2015) · Advances in Pharmacological Sciences · doi:10.1155/2015/507151 · Cited by 258
Heparan sulfate 3-O-sulfation: A rare modification in search of a function
Thacker, B. E., Xu, D., Lawrence, R., & Esko, J. D. (2014) · Matrix Biology · doi:10.1016/j.matbio.2013.12.001 · Cited by 234
Brinkhous, K. M., Smith, H. P., Warner, E. D., & Seegers, W. H. (1939) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1939.125.4.683 · Cited by 234
Linhardt, R. J. (2016) · Frontiers in Bioscience · doi:10.2741/4462 · Cited by 232
Self-citationStevenson, J. L., Choi, S. H., & Varki, A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1131 · Cited by 220
Preventing Bronchoconstriction in Exercise-Induced Asthma with Inhaled Heparin
Ahmed, T., Garrigo, J., & Danta, I. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307083290204 · Cited by 218
Kuderer, N. M., Khorana, A. A., Lyman, G. H., & Francis, C. W. (2007) · Cancer · doi:10.1002/cncr.22892 · Cited by 212
A proteoglycan form of heparin and its degradation to single-chain molecules.
Robinson, H. C., Horner, A. A., Höök, M., Ogren, S., & Lindahl, U. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37973-5 · Cited by 211
Homogeneous low-molecular-weight heparins with reversible anticoagulant activity
Xu, Y., Cai, C., Chandarajoti, K., Hsieh, P.-H., Li, L., Pham, T. Q., Sparkenbaugh, E. M., Sheng, J., Key, N. S., Pawlinski, R., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1459 · Cited by 195
Self-citationLAZO‐LANGNER, A., GOSS, G. D., SPAANS, J. N., & RODGER, M. A. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02427.x · Cited by 191
Multiple functional domains of the heparin molecule.
Oosta, G. M., Gardner, W. T., Beeler, D. L., & Rosenberg, R. D. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.2.829 · Cited by 187
Macbeth, F., Noble, S., Evans, J., Ahmed, S., Cohen, D., Hood, K., Knoyle, D., Linnane, S., Longo, M., Moore, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0268 · Cited by 178
Chung, Y.-I., Kim, J. C., Kim, Y. H., Tae, G., Lee, S.-Y., Kim, K., & Kwon, I. C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.017 · Cited by 175
Factor Xa or thrombin: is factor Xa a better target?
ANSELL, J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02473.x · Cited by 170
Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky, I., Mohsen, M., Lider, O., Cm, S., Hp, E., Vigoda, M., Ishai-Michaeli, R., & Peretz, T. (1994) · PubMed · Cited by 170
Liu, J., Shriver, Z., Pope, R. M., Thorp, S. C., Duncan, M. B., Copeland, R. J., Raska, C. S., Yoshida, K., Eisenberg, R. J., Cohen, G., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202034200 · Cited by 169
Self-citationAnti-cancer properties of low-molecular-weight heparin: Preclinical evidence
Petersen, L., & Mousa, S. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-12-0832 · Cited by 165
The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria
Shaughnessy, S., Young, E., Deschamps, P., et al. (1995) · Blood · doi:10.1182/blood.v86.4.1368.bloodjournal8641368 · Cited by 152
Passirani, C., BARRATT, G. M., Devissaguet, J., & Labarre, D. (1998) · Life Sciences · doi:10.1016/s0024-3205(97)01175-2 · Cited by 141
Lapierre, F., Holme, K. R., Lam, L. H., Tressler, R., Storm, N., Wee, J., Stack, R. J., Castellot, J. J., & Tyrrell, D. J. (1996) · Glycobiology · doi:10.1093/glycob/6.3.355 · Cited by 139
Bioengineered heparins and heparan sulfates
Fu, L., Suflita, M., & Linhardt, R. J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.002 · Cited by 138
Self-citationStevenson, J. L., Varki, A. P., & Borsig, L. (2007) · Thrombosis Research · doi:10.1016/s0049-3848(07)70138-x · Cited by 138
Generation of “Neoheparin” from E. coli K5 Capsular Polysaccharide
Lindahl, U., Li, J., Kusche‐Gullberg, M., Salmivirta, M., Alaranta, S., Veromaa, T., EMEIS, J. J., Roberts, I. S., Taylor, C. M., Oreste, P., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049812m · Cited by 124
Advanced Nanocarriers Based on Heparin and Its Derivatives for Cancer Management
Yang, X., Du, H., Liu, J., & Zhai, G. (2014) · Biomacromolecules · doi:10.1021/bm501532e · Cited by 110
Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells
Jayson, G. C., & Gallagher, J. T. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.3 · Cited by 96
Ang, Y. S., Mahmud, N., White, B., Byrne, M., Kelly, A., Lawler, M., McDonald, G. S. A., Smith, O. P., & Keeling, P. W. N. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00802.x · Cited by 88
Nonanticoagulant heparin inhibits NF-κB activation and attenuates myocardial reperfusion injury
Thourani, V. H., Brar, S. S., Kennedy, T. P., Thornton, L. R., Watts, J. A., Ronson, R. S., Zhao, Z.-Q., Sturrock, A., Hoidal, J. R., & Vinten‐Johansen, J. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.278.6.h2084 · Cited by 83
Cuellar, K., Chuong, H. H., Hubbell, S. M., & Hinsdale, M. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m611048200 · Cited by 81
Metabolic engineering of Chinese hamster ovary cells: Towards a bioengineered heparin
Baik, J. Y., Gasimli, L., Yang, B., Datta, P., Zhang, F., Glass, C. A., Esko, J. D., Linhardt, R. J., & Sharfstein, S. T. (2012) · Metabolic Engineering · doi:10.1016/j.ymben.2012.01.008 · Cited by 74
Self-citationCombinatorial one-pot chemoenzymatic synthesis of heparin
Bhaskar, U., Li, G., Fu, L., Onishi, A., Suflita, M., Dordick, J. S., & Linhardt, R. J. (2014) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2014.10.054 · Cited by 68
Self-citationYang, B., Weyers, A. M., Baik, J. Y., Sterner, E., Sharfstein, S. T., Mousa, S. A., Zhang, F., Dordick, J. S., & Linhardt, R. J. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.04.003 · Cited by 68
Self-citationWalenga, J. M., & Lyman, G. H. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.007 · Cited by 61
New parenteral anticoagulants in development
Gómez‐Outes, A., Suárez-Gea, M. L., Lecumberri, R., Rocha, E. A. V., Pozo-Hernández, C., & Vargas, E. (2010) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944710387808 · Cited by 56
Heparin in the treatment of chronic obstructive bronchopulmonary disease
Boyle, J. P., Smart, R. H., & Shirey, J. K. (1964) · The American Journal of Cardiology · doi:10.1016/0002-9149(64)90100-6 · Cited by 46
Datta, P., Li, G., Yang, B., Zhao, X., Baik, J. Y., Gemmill, T. R., Sharfstein, S. T., & Linhardt, R. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.519033 · Cited by 36
Self-citationBaik, J. Y., Dahodwala, H., Oduah, E., Talman, L., Gemmill, T. R., Gasimli, L., Datta, P., Yang, B., Li, G., Zhang, F., et al. (2015) · Biotechnology Journal · doi:10.1002/biot.201400665 · Cited by 35
Self-citationSudha, T., Phillips, P. G., Kanaan, C. M., Linhardt, R. J., Borsig, L., & Mousa, S. A. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9461-9 · Cited by 35
Self-citationYu, L., Garg, H. G., Li, B., Linhardt, R. J., & Hales, C. A. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791054176 · Cited by 23
Self-citationThe Role of Heparan Sulfate Proteoglycans in Bacterial Infections
Fernández‐Vega, I. (2014) · Journal of Medical Microbiology & Diagnosis · doi:10.4172/2161-0703.1000157 · Cited by 22
Development of a Synthetic Heparin Pentasaccharide: Fondaparinux.
Walenga, J. M., Fareed, J., Jeske, W. P., Bick, R. L., & Samama, M. M. (2002) · PubMed · Cited by 13
Cited by
Brestoff, J. R., Wilen, C. B., Moley, J. R., Li, Y., Zou, W., Malvin, N. P., Rowen, M. N., Saunders, B. T., Ma, H., Mack, M. R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.008 · Cited by 397
Carbohydrate-Based Macromolecular Biomaterials
Su, L., Feng, Y., Wei, K., Xu, X., Liu, R., & Chen, G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01338 · Cited by 335
Glycosaminoglycans from marine sources as therapeutic agents
Valcarcel, J., Novoa-Carballal, R., Pérez-Martín, R. I., Reis, R. L., & Vázquez, J. A. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.07.008 · Cited by 188
Metadata
- Authors
- Oduah, E., Linhardt, R., & Sharfstein, S.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2016-07-04
- Volume
- 9
- Issue
- 3
- Pages
- 38
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W2466124353
- Cited by
- 281
- References
- 58
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.